National Center for Posttraumatic Stress Disorder, Veterans Affairs Medical Center, 215 North Main Street, White River Junction, VT, 05009, USA,
Curr Psychiatry Rep. 2015 Apr;17(4):564. doi: 10.1007/s11920-015-0564-2.
There have been significant advancements in the pharmacologic management of posttraumatic stress disorder (PTSD) in the past two decades. Multisite randomized clinical trials (RCTs) have noted the efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNR Is) for PTSD treatment. Unfortunately, there have been no new medications approved to treat PTSD in the past 10 years. Although there have been exciting new findings in our knowledge of the neurobiology of PTSD, clinical trials testing new medications have lagged. This review summarizes recent research that builds on the unique pathophysiology of PTSD and suggests ways to move the field forward.
在过去的二十年中，创伤后应激障碍（PTSD）的药物治疗取得了重大进展。多中心随机临床试验（RCT）已经注意到选择性 5-羟色胺再摄取抑制剂（SSRIs）和 5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRIs）在 PTSD 治疗中的疗效。不幸的是，在过去的 10 年中，没有新的药物被批准用于治疗 PTSD。尽管我们对 PTSD 的神经生物学有了令人兴奋的新发现，但测试新药物的临床试验却滞后了。这篇综述总结了最近的研究成果，这些研究成果基于 PTSD 的独特病理生理学，并提出了推动该领域前进的方法。
